Conclusions The last 10 years has seen a substantial increase in the number of mapping studies and some evidence of advancement in methods with consideration of models beyond OLS and greater reporting of predictive ability of mapping functions
Background Mapping is an increasingly common method used to predict instrument-specific preference-based health-state utility values ( HSUVs ) from data obtained from another health-related quality of life ( HRQoL ) measure .
There have been several method ological developments in this area since a previous review up to 2007 .
Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy
Background Grass allergen immunotherapy ( AIT ) reduces symptom severity in seasonal allergic rhinoconjunctivitis ( ARC ) but its impact on general health-related utility has not been characterised for the purpose s of economic evaluation . The aim of this study was to model the preferred measure of utility , EQ-5D index , from symptom severity and estimate incremental quality adjusted life years ( QALYs ) associated with SQ-st and ardised grass immunotherapy tablet ( GRAZAX ® , 75,000 SQ-T/2,800 BAU , ALK , Denmark ) . Methods Data were analysed from five consecutive pollen seasons in a r and omised placebo controlled trial of GRAZAX ® . Binomial and Gaussian mixed effects modelling related weekly EQ-5D index score to daily symptom and medication scores ( DSS & DMS respectively ) . In turn , daily EQ-5D index was estimated from ARC symptoms and medication use . Results DSS and DMS were the principal predictors of ‘ perfect ’ health ( EQ-5D = 1.000 ; binomial ) and ‘ imperfect ’ health ( EQ-5D < 1.000 ; Gaussian ) . Each unit increase in DSS and DMS reduced the odds of ‘ perfect ’ health ( EQ-5D = 1.000 ) by 27 % and 16 % respectively , and reduced ‘ imperfect ’ health by 0.17 and 0.13 , respectively . Gender remained the only other significant main fixed effect ( Male odds ratio [ OR ] = 1.82 ) . Incremental estimated EQ-5D index utility  for GRAZAX ® was observed from day -30 to day + 70 of the pooled pollen season ; mean daily utility for GRAZAX ® = 0.938 units ( 95%CI 0.932 - 0.943 ) vs. 0.914 ( 0.907 - 0.921 ) for placebo , an incremental difference of 0.0238 ( p < 0.001 ) . This translates into an incremental 0.0324 Quality Adjusted Life Years over the five year study period . Conclusions ARC symptoms and medication use are the main predictors of EQ-5D index . The incremental QALYs observed for GRAZAX ® may not fully describe the health benefits of this treatment , suggesting that economic modelling may be conservative
Conclusions The last 10 years has seen a substantial increase in the number of mapping studies and some evidence of advancement in methods with consideration of models beyond OLS and greater reporting of predictive ability of mapping functions
Background Mapping is an increasingly common method used to predict instrument-specific preference-based health-state utility values ( HSUVs ) from data obtained from another health-related quality of life ( HRQoL ) measure .
There have been several method ological developments in this area since a previous review up to 2007 .